COO/Director Yi-Kuei Chen Discloses 5.3% Beneficial Ownership, Valued at Over $1.7 Million
Summary
Apollomics Inc.'s COO and Director, Yi-Kuei Chen, has filed an initial Schedule 13D, disclosing beneficial ownership of 5.3% of the company's Class A ordinary shares, primarily through an investment entity and vested equity awards.
Key Events
-
Significant Insider Stake
Yi-Kuei Chen, the Chief Operating Officer and a Director of Apollomics Inc., has disclosed beneficial ownership of 115,171 Class A ordinary shares, representing approximately 5.3% of the outstanding class.
-
Valuation of Holdings
The disclosed beneficial ownership is valued at approximately $1.77 million based on the current stock price, representing over 10% of the company's market capitalization.
-
Sources of Ownership
The stake includes 101,248 shares and 3,823 warrants held by Maxpro Investment Co., Ltd. (an entity Mr. Chen controls), along with 10,000 restricted stock units (RSUs) held directly by Mr. Chen, with 5,000 vesting on February 17, 2026, and another 5,000 vesting on May 17, 2026.
-
Investment Intent
The shares are held for investment purposes, with no current plans for corporate actions, though future acquisitions or dispositions are possible.
Analysis
This initial Schedule 13D filing reveals that Apollomics' Chief Operating Officer and Director, Yi-Kuei Chen, beneficially owns a significant 5.3% stake in the company, valued at over $1.7 million. This substantial ownership, primarily through an investment entity (Maxpro) and vested restricted stock units, signals strong alignment between a key executive's personal financial interests and the company's performance. For a company with a market capitalization of approximately $17 million, this represents over 10% of the company's value held by a single executive. This disclosure follows closely on the heels of the Chairman and CEO providing a $2.0 million convertible note, collectively indicating robust insider commitment and investment in the company's future, which can be a positive signal for investors, especially in a life sciences company seeking to advance its pipeline.
At the time of this filing, APLM was trading at $15.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17M. The 52-week trading range was $3.66 to $42.12. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.